1
|
Yang R, Liu Z, Cao H, Shi Y. LINC01089, suppressed by YY1, inhibits lung cancer progression by targeting miR-301b-3p/HPDG axis. Cell Biol Toxicol 2022; 38:1063-1077. [PMID: 34561789 DOI: 10.1007/s10565-021-09643-8] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2021] [Accepted: 08/09/2021] [Indexed: 01/25/2023]
Abstract
PURPOSE LINC01089 is a newly identified lncRNA and rarely reported in human cancers. Our study aimed to investigate its role in lung cancer. METHODS YY1, LINC01089, and miR-301b-3p levels in lung cancer tissues and cells were assessed using qRT-PCR. Bioinformatics analysis and luciferase reporter, ChIP, and RIP assays were carried out for determining the relationships among YY1, LINC01089, miR-301b-3p, and HPGD. Gain- and loss-of-function assays were carried out to confirm the impacts of LINC01089 and HPDG in lung cancer cells. CCK-8 assay was used to assess cell proliferation rate, and Transwell assay was applied to measure cell invasion and migration. An in vivo tumor model was applied for validating the role of LINC01089. RESULTS LINC01089 was decreased in lung cancer tissues and cells, and low LINC01089 level predicted a poor clinical outcome. YY1 directly bound to LINC01089 promoter region and inhibited its transcription. LINC01089 knockdown thwarted the proliferation, invasion, and migration capacity of H1299 and A549 cells and aggravated tumor growth. Specifically, LINC01089 functioned as a competing endogenous RNA of miR-301b-3p to modulate HPGD and thereby affected lung cancer progression. CONCLUSION Our data revealed that LINC01089, directly suppressed by YY1, inhibited lung cancer progression by targeting the miR-301b-3p/HPGD axis. Graphical abstract 1. LINC01089 expression was downregulated in lung cancer tisuues and cell lines, and low LINC01089 levels predicted a poor clinical outcome. 2. LINC01089 knockdown enhanced proliferation, invasion, and migration of H1299 and A549 cells in vitro and promoted lung cancer cell tumorigenesis and metastasis in vivo. 3. LINC01089, directly suppressed by YY1, functioned as a competing endogenous RNA against miR-301b-3p to increase HPGD expression.
Collapse
Affiliation(s)
- Rusong Yang
- Department of Thoracic Surgery, The Second Affiliated Hospital of Nanjing Medical University, No.121 Jiangjiayuan Road, Gulou District, Nanjing, Jiangsu, 210011, People's Republic of China.
| | - Zhengcheng Liu
- Department of Thoracic Surgery, The Second Affiliated Hospital of Nanjing Medical University, No.121 Jiangjiayuan Road, Gulou District, Nanjing, Jiangsu, 210011, People's Republic of China
| | - Hui Cao
- Department of Thoracic Surgery, The Second Affiliated Hospital of Nanjing Medical University, No.121 Jiangjiayuan Road, Gulou District, Nanjing, Jiangsu, 210011, People's Republic of China
| | - Ye Shi
- Department of Thoracic Surgery, The Second Affiliated Hospital of Nanjing Medical University, No.121 Jiangjiayuan Road, Gulou District, Nanjing, Jiangsu, 210011, People's Republic of China
| |
Collapse
|
2
|
Hu B, Toda K, Wang X, Antczak MI, Smith J, Geboers S, Nishikawa G, Li H, Dawson D, Fink S, Desai AB, Williams NS, Markowitz SD, Ready JM. Orally Bioavailable Quinoxaline Inhibitors of 15-Prostaglandin Dehydrogenase (15-PGDH) Promote Tissue Repair and Regeneration. J Med Chem 2022; 65:15327-15343. [PMID: 36322935 PMCID: PMC9885488 DOI: 10.1021/acs.jmedchem.2c01299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
15-Prostaglandin dehydrogenase (15-PGDH) regulates the concentration of prostaglandin E2 in vivo. Inhibitors of 15-PGDH elevate PGE2 levels and promote tissue repair and regeneration. Here, we describe a novel class of quinoxaline amides that show potent inhibition of 15-PGDH, good oral bioavailability, and protective activity in mouse models of ulcerative colitis and recovery from bone marrow transplantation.
Collapse
Affiliation(s)
- Bin Hu
- Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, Teas75390-9038, United States
| | - Kosuke Toda
- Case Comprehensive Cancer Center, Cleveland, Ohio44106-5065, United States
| | - Xiaoyu Wang
- Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, Teas75390-9038, United States
| | - Monika I Antczak
- Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, Teas75390-9038, United States
| | - Julianne Smith
- Case Comprehensive Cancer Center, Cleveland, Ohio44106-5065, United States
| | - Sophie Geboers
- Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, Teas75390-9038, United States
| | - Gen Nishikawa
- Case Comprehensive Cancer Center, Cleveland, Ohio44106-5065, United States
| | - Hongyun Li
- Case Comprehensive Cancer Center, Cleveland, Ohio44106-5065, United States
| | - Dawn Dawson
- Case Comprehensive Cancer Center, Cleveland, Ohio44106-5065, United States
| | - Stephen Fink
- Case Comprehensive Cancer Center, Cleveland, Ohio44106-5065, United States
| | - Amar B Desai
- Case Comprehensive Cancer Center, Cleveland, Ohio44106-5065, United States
| | - Noelle S Williams
- Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, Teas75390-9038, United States
| | - Sanford D Markowitz
- Case Comprehensive Cancer Center, Cleveland, Ohio44106-5065, United States
- Department of Medicine, Case Western Reserve University, Cleveland, Ohio44106, United States
- Seidman Cancer Center, University Hospitals of Cleveland, Cleveland, Ohio44106, United States
| | - Joseph M Ready
- Department of Biochemistry, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, Teas75390-9038, United States
| |
Collapse
|
3
|
Kostyuk A, Lysenko V, Portiankin A, Nazarenko K, Shvydenko K, Shvydenko T. Alicyclic Annulated Triazoles versus Triazinediones by the Reaction of Cyclic Imidates with Methyl 2-Hydrazinyl-2-oxoacetate. HETEROCYCLES 2022. [DOI: 10.3987/com-21-14612] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
4
|
Mallipeddi PL, Zhang Y, Li H, Markowitz SD, Posner B. Structural Insights into Novel 15-Prostaglandin Dehydrogenase Inhibitors. Molecules 2021; 26:molecules26195903. [PMID: 34641449 PMCID: PMC8512612 DOI: 10.3390/molecules26195903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2021] [Revised: 09/24/2021] [Accepted: 09/26/2021] [Indexed: 11/16/2022] Open
Abstract
We discovered SW033291 in a high throughput chemical screen aimed at identifying 15-prostaglandin dehydrogenase (15-PGDH) modulators. The compound exhibited inhibitory activity in in vitro biochemical and cell-based assays of 15-PGDH activity. We subsequently demonstrated that this compound, and several analogs thereof, are effective in in vivo mouse models of bone marrow transplant, colitis, and liver regeneration, where increased levels of PGE2 positively potentiate tissue regeneration. To better understand the binding of SW033291, we carried out docking studies for both the substrate, PGE2, and an inhibitor, SW033291, to 15-PGDH. Our models suggest similarities in the ways that PGE2 and SW033291 interact with key residues in the 15-PGDH-NAD+ complex. We carried out molecular dynamics simulations (MD) of SW033291 bound to this complex, in order to understand the dynamics of the binding interactions for this compound. The butyl side chain (including the sulfoxide) of SW033291 participates in crucial binding interactions that are similar to those observed for the C15-OH and the C16-C20 alkyl chain of PGE2. In addition, interactions with residues Ser138, Tyr151, and Gln148 play key roles in orienting and stabilizing SW033291 in the binding site and lead to enantioselectivity for the R-enantiomer. Finally, we compare the binding mode of (R)-S(O)-SW033291 with the binding interactions of published 15-PGDH inhibitors.
Collapse
Affiliation(s)
- Prema L. Mallipeddi
- Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA;
| | - Yongyou Zhang
- Department of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA; (Y.Z.); (H.L.); (S.D.M.)
| | - Hongyun Li
- Department of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA; (Y.Z.); (H.L.); (S.D.M.)
| | - Sanford D. Markowitz
- Department of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA; (Y.Z.); (H.L.); (S.D.M.)
- Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA
- Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
| | - Bruce Posner
- Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA;
- Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
- Correspondence:
| |
Collapse
|
5
|
Zhang S, Xiao J, Chen X, Li Y. Insulation and Flame Retardancy Improvement of PBDEs Using 3D-QSAR Model Combined with a Fuzzy Membership Function Method. Chem Res Chin Univ 2021. [DOI: 10.1007/s40242-021-0358-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
6
|
Yang SM, Martinez NJ, Yasgar A, Danchik C, Johansson C, Wang Y, Baljinnyam B, Wang AQ, Xu X, Shah P, Cheff D, Wang XS, Roth J, Lal-Nag M, Dunford JE, Oppermann U, Vasiliou V, Simeonov A, Jadhav A, Maloney DJ. Discovery of Orally Bioavailable, Quinoline-Based Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors with Potent Cellular Activity. J Med Chem 2018; 61:4883-4903. [PMID: 29767973 PMCID: PMC6004562 DOI: 10.1021/acs.jmedchem.8b00270] [Citation(s) in RCA: 58] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
![]()
Aldehyde
dehydrogenases (ALDHs) are responsible for the metabolism of aldehydes
(exogenous and endogenous) and possess vital physiological and toxicological
functions in areas such as CNS, inflammation, metabolic disorders,
and cancers. Overexpression of certain ALDHs (e.g., ALDH1A1) is an
important biomarker in cancers and cancer stem cells (CSCs) indicating
the potential need for the identification and development of small
molecule ALDH inhibitors. Herein, a newly designed series of quinoline-based
analogs of ALDH1A1 inhibitors is described. Extensive medicinal chemistry
optimization and biological characterization led to the identification
of analogs with significantly improved enzymatic and cellular ALDH
inhibition. Selected analogs, e.g., 86 (NCT-505) and 91 (NCT-506), demonstrated target engagement in a cellular
thermal shift assay (CETSA), inhibited the formation of 3D spheroid
cultures of OV-90 cancer cells, and potentiated the cytotoxicity of
paclitaxel in SKOV-3-TR, a paclitaxel resistant ovarian cancer cell
line. Lead compounds also exhibit high specificity over other ALDH
isozymes and unrelated dehydrogenases. The in vitro ADME profiles and pharmacokinetic evaluation of selected analogs
are also highlighted.
Collapse
Affiliation(s)
- Shyh-Ming Yang
- National Center for Advancing Translational Sciences, National Institutes of Health , 9800 Medical Center Drive , Rockville , Maryland 20850 , United States
| | - Natalia J Martinez
- National Center for Advancing Translational Sciences, National Institutes of Health , 9800 Medical Center Drive , Rockville , Maryland 20850 , United States
| | - Adam Yasgar
- National Center for Advancing Translational Sciences, National Institutes of Health , 9800 Medical Center Drive , Rockville , Maryland 20850 , United States
| | - Carina Danchik
- National Center for Advancing Translational Sciences, National Institutes of Health , 9800 Medical Center Drive , Rockville , Maryland 20850 , United States
| | - Catrine Johansson
- Centre for Translational Myeloma Research, Botnar Research Centre, Oxford NIHR BRU , University of Oxford , Oxford OX3 7LD , U.K
| | - Yuhong Wang
- National Center for Advancing Translational Sciences, National Institutes of Health , 9800 Medical Center Drive , Rockville , Maryland 20850 , United States
| | - Bolormaa Baljinnyam
- National Center for Advancing Translational Sciences, National Institutes of Health , 9800 Medical Center Drive , Rockville , Maryland 20850 , United States
| | - Amy Q Wang
- National Center for Advancing Translational Sciences, National Institutes of Health , 9800 Medical Center Drive , Rockville , Maryland 20850 , United States
| | - Xin Xu
- National Center for Advancing Translational Sciences, National Institutes of Health , 9800 Medical Center Drive , Rockville , Maryland 20850 , United States
| | - Pranav Shah
- National Center for Advancing Translational Sciences, National Institutes of Health , 9800 Medical Center Drive , Rockville , Maryland 20850 , United States
| | - Dorian Cheff
- National Center for Advancing Translational Sciences, National Institutes of Health , 9800 Medical Center Drive , Rockville , Maryland 20850 , United States
| | - Xinran S Wang
- National Center for Advancing Translational Sciences, National Institutes of Health , 9800 Medical Center Drive , Rockville , Maryland 20850 , United States
| | - Jacob Roth
- National Center for Advancing Translational Sciences, National Institutes of Health , 9800 Medical Center Drive , Rockville , Maryland 20850 , United States
| | - Madhu Lal-Nag
- National Center for Advancing Translational Sciences, National Institutes of Health , 9800 Medical Center Drive , Rockville , Maryland 20850 , United States
| | - James E Dunford
- Centre for Translational Myeloma Research, Botnar Research Centre, Oxford NIHR BRU , University of Oxford , Oxford OX3 7LD , U.K
| | - Udo Oppermann
- Centre for Translational Myeloma Research, Botnar Research Centre, Oxford NIHR BRU , University of Oxford , Oxford OX3 7LD , U.K
| | - Vasilis Vasiliou
- Department of Environmental Health Sciences , Yale School of Public Health , 60 College Street , New Haven , Connecticut 06510 , United States
| | - Anton Simeonov
- National Center for Advancing Translational Sciences, National Institutes of Health , 9800 Medical Center Drive , Rockville , Maryland 20850 , United States
| | - Ajit Jadhav
- National Center for Advancing Translational Sciences, National Institutes of Health , 9800 Medical Center Drive , Rockville , Maryland 20850 , United States
| | - David J Maloney
- National Center for Advancing Translational Sciences, National Institutes of Health , 9800 Medical Center Drive , Rockville , Maryland 20850 , United States
| |
Collapse
|
7
|
Qi X, Wang Y, Hou J, Huang Y. A Single Nucleotide Polymorphism in HPGD Gene Is Associated with Prostate Cancer Risk. J Cancer 2017; 8:4083-4086. [PMID: 29187884 PMCID: PMC5706011 DOI: 10.7150/jca.22025] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2017] [Accepted: 08/26/2017] [Indexed: 01/18/2023] Open
Abstract
Introduction: The HPGD gene was associated with some cancers, such as colorectal, breast, prostate, and bladder. However, detailed role of 15-hydroxyprostaglandin dehydrogenase (HPGD) gene remain unclear in prostate cancer. The study was to investigate the correlation between rs8752 that located in the 3'untranslated region (UTR) of the 15-hydroxyprostaglandin dehydrogenase (HPGD) gene and prostate cancer (PCa) risk. Materials and Methods: 109 patients from the First Affiliate Hospital of Soochow University were recruited. According to the results of pathologic diagnosis, all patients were divided into two groups (prostate cancer and benign prostatic hyperplasia). The single-nucleotide polymorphism (SNP) rs8752 was genotyped in all samples by direct sequencing. Results: 54 prostate cancer and 55 BPH patients were included with a median age of 70.41 and 67.62 years, respectively. No statistically significant difference between two groups in patient criteria. The frequency of the GG homozygote and AG+GG genotype were 37.74% and 62.26% in 54 prostate cancer samples, while in 55BPH patients, values were 62.50% and 37.50%. Compared with the GG genotype, the combined GA+AA genotypes had a significantly higher risk of prostate cancer (OR = 2.750; 95% CI: 1.266-5.971, p = 0.011). Furthermore, the risk effect was obtained in subgroups of PCa patient group, the AA+AG genotypes significantly associated with the higher Gleason score samples (AA+AG vs GG: OR = 3.50, 95%CI = 1.106-11.072, p = 0.033) and the risk of pathological stage (AA+AG vs GG: OR = 4.00, 95%CI = 1.253-12.767, p = 0.019). Conclusions: rs8752 in the 3'untranslated region (UTR) of the 15-hydroxyprostaglandin dehydrogenase (HPGD) gene was found to be responsible for the susceptibility to prostate cancer in Chinese individuals.
Collapse
Affiliation(s)
- Xiaofei Qi
- Department of Urology, the First Affiliate Hospital of Soochow University, Suzhou, China
| | - Yu Wang
- Department of Urology, the First Affiliate Hospital of Soochow University, Suzhou, China
| | - Jianquan Hou
- Department of Urology, the First Affiliate Hospital of Soochow University, Suzhou, China
| | - Yuhua Huang
- Department of Urology, the First Affiliate Hospital of Soochow University, Suzhou, China
| |
Collapse
|
8
|
Antczak MI, Zhang Y, Wang C, Doran J, Naidoo J, Voruganti S, Williams NS, Markowitz SD, Ready JM. Inhibitors of 15-Prostaglandin Dehydrogenase To Potentiate Tissue Repair. J Med Chem 2017; 60:3979-4001. [PMID: 28398755 DOI: 10.1021/acs.jmedchem.7b00271] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
The enzyme 15-prostaglandin dehydrogenase (15-PGDH) catalyzes the first step in the degradation of prostaglandins including PGE2. It is a negative regulator of tissue repair and regeneration in multiple organs. Accordingly, inhibitors of 15-PGDH are anticipated to elevate in vivo levels of PGE2 and to promote healing and tissue regeneration. The small molecule SW033291 (1) inhibits 15-PGDH with Ki = 0.1 nM in vitro, doubles PGE2 levels in vivo, and shows efficacy in mouse models of recovery from bone marrow transplantation, ulcerative colitis, and partial hepatectomy. Here we describe optimized variants of 1 with improved solubility, druglike properties, and in vivo activity.
Collapse
Affiliation(s)
- Monika I Antczak
- Department of Biochemistry, UT Southwestern Medical Center , 5323 Harry Hines Boulevard, Dallas, Texas 75390-9038, United States
| | - Yongyou Zhang
- Department of Medicine, Case Western Reserve University , Cleveland, Ohio 44106, United States
| | - Changguang Wang
- Department of Biochemistry, UT Southwestern Medical Center , 5323 Harry Hines Boulevard, Dallas, Texas 75390-9038, United States
| | - Jennifer Doran
- Department of Biochemistry, UT Southwestern Medical Center , 5323 Harry Hines Boulevard, Dallas, Texas 75390-9038, United States
| | - Jacinth Naidoo
- Department of Biochemistry, UT Southwestern Medical Center , 5323 Harry Hines Boulevard, Dallas, Texas 75390-9038, United States
| | - Sukesh Voruganti
- Department of Biochemistry, UT Southwestern Medical Center , 5323 Harry Hines Boulevard, Dallas, Texas 75390-9038, United States
| | - Noelle S Williams
- Department of Biochemistry, UT Southwestern Medical Center , 5323 Harry Hines Boulevard, Dallas, Texas 75390-9038, United States
| | - Sanford D Markowitz
- Department of Medicine, Case Western Reserve University , Cleveland, Ohio 44106, United States.,Seidman Cancer Center, University Hospitals of Cleveland , Cleveland, Ohio 44106, United States.,Case Comprehensive Cancer Center, Case Western Reserve University , Cleveland, Ohio 44106, United States
| | - Joseph M Ready
- Department of Biochemistry, UT Southwestern Medical Center , 5323 Harry Hines Boulevard, Dallas, Texas 75390-9038, United States
| |
Collapse
|
9
|
Hall MD, Simeonov A, Davis MI. Avoiding Fluorescence Assay Interference-The Case for Diaphorase. Assay Drug Dev Technol 2016; 14:175-9. [PMID: 27078679 PMCID: PMC4840916 DOI: 10.1089/adt.2016.707] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
Fluorescence is utilized as the output for a range of assay formats used in high-throughput screening (HTS). Interference with these assays from the compounds in libraries utilized in HTS is a well-recognized phenomenon, particularly for assays relying on UV excitation such as for direct detection of the oxidoreductase cofactors NADH or NADPH. In this study, we discuss these interference challenges and highlight the specific case of the diaphorase/resazurin system that can be coupled to enzymes utilizing NADH or NADPH. We review the utilization of this assay system in the literature and argue that the diaphorase/resazurin system is underutilized in assay development. It is the authors' hope that this Perspective and the accompanying Technical Brief in this issue will stimulate interest in a robust and sensitive coupling system to avoid assay fluorescence interference.
Collapse
Affiliation(s)
- Matthew D Hall
- NCATS Chemical Genomics Center, National Center for Advancing Translational Sciences, National Institutes of Health , Rockville, Maryland
| | - Anton Simeonov
- NCATS Chemical Genomics Center, National Center for Advancing Translational Sciences, National Institutes of Health , Rockville, Maryland
| | - Mindy I Davis
- NCATS Chemical Genomics Center, National Center for Advancing Translational Sciences, National Institutes of Health , Rockville, Maryland
| |
Collapse
|
10
|
Gholap SS. Pyrrole: An emerging scaffold for construction of valuable therapeutic agents. Eur J Med Chem 2015; 110:13-31. [PMID: 26807541 DOI: 10.1016/j.ejmech.2015.12.017] [Citation(s) in RCA: 228] [Impact Index Per Article: 25.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2014] [Revised: 12/05/2015] [Accepted: 12/10/2015] [Indexed: 12/20/2022]
Abstract
Pyrrole derivatives comprise a class of biologically active heterocyclic compounds which can serve as promising scaffolds for antimicrobial, antiviral, antimalarial, antitubercular, anti-inflammatory and enzyme inhibiting drugs. Due to their inimitable anticancer and anti-tubercular properties, researchers were inspired to develop novel pyrrole derivatives for the treatment of MDR pathogens. In the present review the main target is to focus on the development of pyrrole mimics, with emphasis based on their structure activity relationship (SAR). The present review is being obliging for the future development of pyrrole therapeutics.
Collapse
Affiliation(s)
- Somnath S Gholap
- Department of Chemistry, Padmashri Vikhe Patil College, Pravaranagar (Loni kd.), Rahata, Ahmednagar, 413713, Maharashtra, India.
| |
Collapse
|
11
|
Yang SM, Yasgar A, Miller B, Lal-Nag M, Brimacombe K, Hu X, Sun H, Wang A, Xu X, Nguyen K, Oppermann U, Ferrer M, Vasiliou V, Simeonov A, Jadhav A, Maloney DJ. Discovery of NCT-501, a Potent and Selective Theophylline-Based Inhibitor of Aldehyde Dehydrogenase 1A1 (ALDH1A1). J Med Chem 2015; 58:5967-78. [PMID: 26207746 PMCID: PMC5185321 DOI: 10.1021/acs.jmedchem.5b00577] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Aldehyde dehydrogenases (ALDHs) metabolize reactive aldehydes and possess important physiological and toxicological functions in areas such as CNS, metabolic disorders, and cancers. Increased ALDH (e.g., ALDH1A1) gene expression and catalytic activity are vital biomarkers in a number of malignancies and cancer stem cells, highlighting the need for the identification and development of small molecule ALDH inhibitors. A new series of theophylline-based analogs as potent ALDH1A1 inhibitors is described. The optimization of hits identified from a quantitative high throughput screening (qHTS) campaign led to analogs with improved potency and early ADME properties. This chemotype exhibits highly selective inhibition against ALDH1A1 over ALDH3A1, ALDH1B1, and ALDH2 isozymes as well as other dehydrogenases such as HPGD and HSD17β4. Moreover, the pharmacokinetic evaluation of selected analog 64 (NCT-501) is also highlighted.
Collapse
Affiliation(s)
- Shyh-Ming Yang
- National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States
| | - Adam Yasgar
- National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States
| | - Bettina Miller
- Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045, United States
| | - Madhu Lal-Nag
- National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States
| | - Kyle Brimacombe
- National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States
| | - Xin Hu
- National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States
| | - Hongmao Sun
- National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States
| | - Amy Wang
- National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States
| | - Xin Xu
- National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States
| | - Kimloan Nguyen
- National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States
| | - Udo Oppermann
- Botnar Research Center, NIHR Oxford Biomedical Research Unit, Oxford OX3 7LD, U.K
- Structural Genomics Consortium, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford OX3 7DQ, U.K
| | - Marc Ferrer
- National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States
| | - Vasilis Vasiliou
- Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045, United States
- Department of Environmental Health Sciences, Yale School of Public Health, 60 College Street, New Haven, Connecticut 06510, United States
| | - Anton Simeonov
- National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States
| | - Ajit Jadhav
- National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States
| | - David J. Maloney
- National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States
| |
Collapse
|
12
|
Gromov P, Espinoza JA, Gromova I. Molecular and diagnostic features of apocrine breast lesions. Expert Rev Mol Diagn 2015; 15:1011-22. [DOI: 10.1586/14737159.2015.1057125] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|